Nanexa
Logotype for Nanexa

Nanexa (NANEXA) investor relations material

Nanexa Q4 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Nanexa
Q4 2025 earnings summary19 Feb, 2026

Executive summary

  • Secured a major license and option agreement with Moderna for PharmaShell®-based products, including an initial USD 3 million payment and potential milestones up to USD 500 million plus royalties.

  • Transitioned focus in NEX-22 project from liraglutide to semaglutide, targeting monthly and quarterly dosing for type 2 diabetes and obesity.

  • Achieved finalist status in the Fierce Life Sciences Innovation Awards for drug delivery technology.

  • Announced breakthrough preclinical data for monthly semaglutide formulation post-period.

Financial highlights

  • Q4 2025 turnover: SEK 30,090 thousand (up from SEK 4,517 thousand YoY), with SEK 27,999 thousand from Moderna agreement.

  • Q4 2025 EBIT: SEK 16,665 thousand (vs. -12,025 thousand YoY); profit after tax: SEK 16,036 thousand (vs. -11,631 thousand YoY).

  • FY 2025 turnover: SEK 36,149 thousand (up from SEK 24,361 thousand YoY); EBIT: SEK -8,768 thousand (vs. -26,062 thousand YoY); net loss: SEK -11,388 thousand (vs. -24,905 thousand YoY).

  • Cash and cash equivalents at year-end: SEK 44,567 thousand (vs. SEK 10,292 thousand YoY).

  • Cash flow for the year: SEK 34,276 thousand (vs. -54,877 thousand YoY).

Outlook and guidance

  • Board believes current working capital and cash are sufficient to finance operations until early 2027.

  • Focus remains on securing further revenue from pharma agreements and advancing business development, especially for semaglutide and GLP-1 projects.

  • No dividend proposed for 2025.

What is the scope of the Moderna collaboration?
How does PharmaShell mitigate GLP-1 side effects?
What is the plan for post-early 2027 funding?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Nanexa earnings date

Logotype for Nanexa
Q1 202629 Apr, 2026
Nanexa
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Nanexa earnings date

Logotype for Nanexa
Q1 202629 Apr, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Nanexa AB focuses on developing nanoparticle technology for drug delivery. The company utilizes their proprietary NxCore platform to transform drugs from conventional to nanomedicines. Their lead product candidate is Nanoxel, a nanomedicine that targets oral mucositis, a common and exceptionally debilitating side effect in cancer patients receiving chemotherapy and radiation therapies; and angina pectoris and heart failure caused by atherosclerosis, a build-up of plaque in the blood vessels. The company intends to transform new products into nanomedicines or develop completely new nanomedicines.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage